APA

Patel H., Periyasamy M., Sava G. P., Bondke A., Slafer B. W., Kroll S. H. B., Barbazanges M., Starkey R., Ottaviani S., Harrod A., Aboagye E. O., Buluwela L., Fuchter M. J., Barrett A. G. M., Coombes R. C. & Ali S. (20190625). ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. : Molecular cancer therapeutics.

Chicago

Patel Hetal, Periyasamy Manikandan, Sava Georgina P, Bondke Alexander, Slafer Brian W, Kroll Sebastian H B, Barbazanges Marion, Starkey Richard, Ottaviani Silvia, Harrod Alison, Aboagye Eric O, Buluwela Laki, Fuchter Matthew J, Barrett Anthony G M, Coombes R Charles and Ali Simak. 20190625. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. : Molecular cancer therapeutics.

Harvard

Patel H., Periyasamy M., Sava G. P., Bondke A., Slafer B. W., Kroll S. H. B., Barbazanges M., Starkey R., Ottaviani S., Harrod A., Aboagye E. O., Buluwela L., Fuchter M. J., Barrett A. G. M., Coombes R. C. and Ali S. (20190625). ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. : Molecular cancer therapeutics.

MLA

Patel Hetal, Periyasamy Manikandan, Sava Georgina P, Bondke Alexander, Slafer Brian W, Kroll Sebastian H B, Barbazanges Marion, Starkey Richard, Ottaviani Silvia, Harrod Alison, Aboagye Eric O, Buluwela Laki, Fuchter Matthew J, Barrett Anthony G M, Coombes R Charles and Ali Simak. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. : Molecular cancer therapeutics. 20190625.